Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.625 USD | +3.02% |
|
+20.76% | +30.40% |
07-02 | Inozyme Pharma Says US FDA Granted Fast Track Designation to INZ-701 to Treat ABCC6 Deficiency | MT |
07-02 | Inozyme Pharma Gets FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.40% | 338M | |
+25.37% | 46.56B | |
+45.38% | 41.67B | |
+0.29% | 41.16B | |
+33.21% | 32.4B | |
+20.83% | 28.18B | |
-6.35% | 28.1B | |
+49.08% | 14.52B | |
+47.45% | 13.74B | |
+3.10% | 12.17B |
- Stock Market
- Equities
- INZY Stock
- News Inozyme Pharma, Inc.
- Jefferies & Co. Initiates Inozyme Pharma, Inc at Hold, Price Target Set at $5